Clinical and laboratory factors underlying refractoriness to platelet transfusions

Journal of Clinical Apheresis

Volumn 11, Issue 3, 1996, Pages 143-148

  Friedberg, Richard C ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

alloimmunization; apheresis; crossmatch; outcomes; platelets; transfusion

Indexed keywords

AMPHOTERICIN B; HLA ANTIBODY; HLA ANTIGEN;

ALLOIMMUNIZATION; APHERESIS; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL PROTOCOL; CONFERENCE PAPER; HEALTH CARE COST; HLA TYPING; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

AUTOIMMUNITY; BLOOD BANKS; HISTOCOMPATIBILITY TESTING; HUMANS; PLATELET TRANSFUSION;

EID: 0029824015     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1101(1996)11:3<143::AID-JCA5>3.0.CO;2-B     Document Type: Conference Paper

References (23)

1. Brubaker DB: Refractoriness to platelet transfusions. AJCP 91:500-501, 1989.
2. Friedberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD: Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 81:3428-3434, 1993.
3. Taaning E, Skibsted L: The frequency of platelet alloantibodies in pregnant women and the occurrence and management of neonatal alloimmune thrombocytopenic purpura. Obstet Gynecol Surv 45:521-525, 1990.
4. Gluckman E: Umbilical cord blood biology and transplantation. Curr Opin Hematol 2:413-416, 1995.
5. Bolgiano DC, Larson EB, Slichter SJ: A model to determine required pool size for HLA-typed community donor apheresis programs. Transfusion 29:306-310, 1989.
6. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman J-WN: Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 77:201-205, 1991.
7. Brubaker DB, Romine M: Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platlet therapy. Am J Hematol 26:341-352, 1987.
8. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet 338:1223-1226, 1991.
9. Beutler E: Platelet transfusions: The 20,000/μL trigger. Blood 81:1411-1413, 1993.
10. Friedberg RC, Mintz PD: Causes of refractoriness to platelet transfusion. Curr Opin Hematol 2:193-198, 1995.
11. Pisciotto PT, Benson K, Hume H, Glassman AB, Oberman H, Popovsky M, Hines D, Anderson K: Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 35:498-502, 1995.
12. Novotny VMJ, van Doom R, Witvliet MD, Claas FHJ, Brand A: Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 85:1736-1741, 1995.
13. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, Van Dijk BA, van Putten WLJ, Claas FHJ, Novotny VMJ, Brand A: Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 85:824-828, 1995.
14. Klingemann HG, Self S, Banaji M, Deeg HJ, Doney K, Slichter SJ, Thomas ED, Storb RF: Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. Br J Haematol 66:115-121, 1987.
15. Bishop JF, McGrath KM, Wolf MM, Matthews JP, De Luise T, Holdsworth RF, Yuen K, Veale M, Whiteside MG, Cooper IA, et al.: Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 71:383-387, 1988.
16. Bishop JF, Matthews JR McGrath K, Yuen K, Wolf MM, Szer J: Factors influencing 20-hour increments after platelet transfusion. Transfusion 31:392-396. 1991
17. Oksanen K: Leukocyte-depleted blood components prevent platelet refractoriness in patients with acute myeloid leukemia. Eur J Haematol 53:100-107, 1994.
18. Williamson LM, Wimperis JZ, Williamson P, Copplestone JA, Gooi HC, Morgenstern GR, Norfolk DR: Bedside filtration of blood products in the prevention of HLA alloimmunization - a prospective randomized study. Blood 83:3028-3035, 1994.
19. Oksanen K, Kekomaki R, Ruutu T, Koskimies S, Myllyla G: Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - a randomized trial. Transfusion 31:588-594, 1991.
20. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR: Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 71:1402-1417, 1988.
21. Andreu G, Dewailly J, Leberre C, Quarre MC, Bidet ML, Tardivel R, Devers L, Lam Y, Soreau E, Boccaccio C, et al.: Prevention of HLA immunization with leucocyte-poor packed red cells and platelet concentrates prepared by filtration. Blood 72:964-969. 1988.
22. Doughty DA, Murphy MF, Metcalfe P, Rohatiner AZS, Lister TA, Waters AH: Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 66:200-205, 1994.
23. Moroff G, Garratty G, Heal JM, MacPherson BR, Stroncek D, Huang ST, Ho W, Petz LD, Leach MF, Lennon SS, et al.: Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 32:633-640, 1992.